SCHEMBL15965621

SCHEMBL15965621

CCC1O[C@@H](OCc2ccccc2)C(OC(=O)c2ccccc2)[C@@H](C)[C@@H]1O[C@@H]1OC(CO)[C@H](O)[C@H](O)C1OC(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 3/20 0.45
▸ LGALS9 O00182 2/20 0.45
▸ LGALS1 P09382 2/20 0.45
▸ LGALS7; LGALS7B P47929 2/20 0.45
▸ SLC6A2 P23975 1/20 0.43
▸ SELP P16109 8/20 0.42
▸ LGALS8 O00214 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ SELE P16581 3/20 0.41
▸ LGALS4 P56470 1/20 0.39
▸ FGF1 P05230 1/20 0.38
▸ FGF2 P09038 1/20 0.38
▸ VEGFA P15692 1/20 0.38
▸ HPSE Q9Y251 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15965619 0.91 TYMP (0.40) LGALS3LGALS9LGALS1LGALS7; LGALS7BSLC6A2
SCHEMBL18114326 0.87 LGALS3 (0.57) LGALS3LGALS9LGALS1LGALS7; LGALS7BSLC6A2
SCHEMBL14683530 0.86 LGALS3 (0.45) LGALS3LGALS9LGALS1LGALS7; LGALS7BSLC6A2
SCHEMBL15965615 0.85 NT5E (0.39) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL26130199 0.83 LGALS3 (0.55) LGALS3LGALS9LGALS1LGALS7; LGALS7BSLC6A2
SCHEMBL15952812 0.83 LGALS3 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BSLC6A2
SCHEMBL15952811 0.83 LGALS3 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BSLC6A2
SCHEMBL15965629 0.82 POLB (0.41) SELPSELEFGF1FGF2VEGFA
SCHEMBL15965626 0.81 LGALS3 (0.44) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL15965622 0.81 POLB (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140235850-A1 SYNTHESIS OF HMO CORE STRUCTURES GLYCOM A/S (DK) 2014-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235850-A1 SYNTHESIS OF HMO CORE STRUCTURES GNE, OGT, GALE LGALS3 165/4885LGALS9 233/4885LGALS1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback